Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:SDY CNSX:VP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSDYSPDR S&P Dividend ETF$148.17-0.7%$147.51$132.89▼$156.39$21.68B0.71261,888 shs174,911 shsVPVodis Pharmaceuticals$0.00$0.16▼$0.62N/AN/A1,714 shs51,582 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSDYSPDR S&P Dividend ETF0.00%-0.47%-0.54%-4.26%+10.97%VPVodis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSDYSPDR S&P Dividend ETF$148.17-0.7%$147.51$132.89▼$156.39$21.68B0.71261,888 shs174,911 shsVPVodis Pharmaceuticals$0.00$0.16▼$0.62N/AN/A1,714 shs51,582 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSDYSPDR S&P Dividend ETF0.00%-0.47%-0.54%-4.26%+10.97%VPVodis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSDYSPDR S&P Dividend ETF 2.44Hold$149.26N/AVPVodis Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSDYSPDR S&P Dividend ETFN/AN/AN/AN/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSDYSPDR S&P Dividend ETFN/AN/A19.85N/AN/AN/AN/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthSDYSPDR S&P Dividend ETF$3.692.47%N/AN/AN/AVPVodis PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSDYSPDR S&P Dividend ETF43.42%VPVodis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipSDYSPDR S&P Dividend ETFN/AVPVodis PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSDYSPDR S&P Dividend ETFN/A146.35 millionN/ANot OptionableVPVodis PharmaceuticalsN/AN/AN/ANot OptionableHSS, VP, AA4, and SDY HeadlinesRecent News About These CompaniesVP debate 'spin room' scene: Talking points and unscripted momentsOctober 22, 2024 | usatoday.comPharma execs donated more to Democrats in campaign’s final stretchOctober 21, 2024 | statnews.comSVitalPath hires Nicole Ramus as global sales VPOctober 18, 2024 | medicaldesignandoutsourcing.comMVice President Harris in ‘Excellent Health,’ Medical Report StatesOctober 14, 2024 | msn.comVance Confident, Walz Uneven in VP Debate Heavy on PolicyOctober 2, 2024 | wsj.comRead the full VP debate transcript from the Walz-Vance showdownOctober 2, 2024 | cbsnews.comAs Investigations Swirl, Another Adams Official ResignsSeptember 24, 2024 | nytimes.comTHE CONTRERAS REPORT: Governor Newsom, veto Big Pharma’s grab for more profitsSeptember 24, 2024 | ivpressonline.comITris Pharma Promotes Naidu to Chief Commercial OfficerSeptember 21, 2024 | njbmagazine.comNNo one used to care about the vice presidency. Here's how (and why) that's changed.September 15, 2024 | pbs.orgPTonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial OperationsSeptember 10, 2024 | markets.businessinsider.comKalVista Pharma Appoints Brian Piekos As New CFOSeptember 10, 2024 | markets.businessinsider.comFor pharma, Trump versus Harris is a showdown between two industry foesAugust 27, 2024 | politifact.comPAvive names Katerina Miras as VP of marketingAugust 21, 2024 | massdevice.comThis Bipartisan Bill Would Upend America's Pharmaceutical IndustryAugust 20, 2024 | forbes.comHow they are reporting it: Kamala Harris' VP pick, Tim WalzAugust 9, 2024 | reuters.comKamala Harris campaign expected to announce VP running mate Tuesday morningAugust 7, 2024 | cbsnews.comVP Pick Walz’s Healthcare Policies Align With Harris’s RecordAugust 7, 2024 | forbes.comWhere VP picks stand on pharmaceutical costsAugust 6, 2024 | beckershospitalreview.comBWhere Harris' VP Options Stand on HealthcareAugust 2, 2024 | msn.comNew MarketBeat Followers Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20265 Robotics Stocks to Watch as Physical AI Builds MomentumBy Ryan Hasson | May 18, 2026HSS, VP, AA4, and SDY Company DescriptionsSPDR S&P Dividend ETF NYSEARCA:SDY$148.17 -1.09 (-0.73%) As of 02:29 PM EasternThe SPDR S&P Dividend ETF seeks to closely match the returns and characteristics of the S&P High Yield Dividend Aristocrats Index (the Index). The Index is designed to measure the performance of the 60 highest dividend yielding S&P Composite 1500 Index constituents that have followed a managed-dividends policy of consistently increasing dividends every year for at least 25 consecutive years. The Fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by the Adviser). SSgA Funds Management, Inc. is the investment adviser to the Fund.Vodis Pharmaceuticals CNSX:VPVodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
